Faster‐acting insulin aspart versus insulin aspart for adults with type 1 diabetes treated with non‐automated insulin pump and continuous glucose monitoring—A double‐blind randomized controlled crossover trial
Primary result · TIRResult — go to the resultBaseline-adjusted estimated treatment difference 6.0 % 95% CI 2.2–9.9Authors' conclusion
Faster aspart improved baseline-adjusted TIR, TAR, CV and HbA1c after 16 weeks with frequent insulin pump adjustments but had a higher incidence of injection site reactions.
Study context
- Population
- Adults with T1D using a non-automated insulin pump and continuous glucose monitoring (CGM); median age 54 years, T1D duration 27 years, HbA1c 59 mmol/mol (7.5%)crossover
- Participants
- 40 adults
- Comparison
- Faster aspart vs insulin aspart in non-automated insulin pump with CGM
- Primary endpoint
- TIR (3.9-10.0 mmol/L)
- Follow-up
- Study end (16 weeks)
Methodological detailsdouble-blind, crossover, 3-week washout between 16-week periods; pump settings adjusted every 3 weeks
- Double-blind
- Crossover
- 3-week washout between 16-week periods; pump settings adjusted every 3 weeks
Primary result
TIR · study end
Baseline-adjusted estimated treatment difference
6.0 %
95% CI 2.2–9.9
P = 0.002
By group
Faster aspartvs Insulin aspart
baseline-adjusted estimated treatment difference 6.0 % (95% CI 2.2–9.9); P = 0.002
As reported in the abstract
Secondary outcomes
| Outcome | Baseline-adjusted ETD (%) (CI) | P value | |
|---|---|---|---|
| TAR (>10.0 mmol/L)In favour of faster aspart | −5.7 (−9.8 to −1.6) | P = 0.007 | |
| TBR (<3.9 mmol/L)In favour of faster aspart | −0.4 (−1.1 to 0.4) | P = 0.30 | |
| −10−505Difference, % (linear scale) |
CV
P = 0.02
| Outcome | ETD (mmol/mol) (CI) | P value | |
|---|---|---|---|
| HbA1c−0.18% (−0.34;−0.02) | −1.9 (−3.7 to −0.2) | P = 0.03 | |
| −4−202Difference, mmol/mol (linear scale) |
Safety
| Outcome | P value |
|---|---|
| Injection site reactionsMore with faster aspart | P = 0.03 |
Severe adverse events incl. severe hypoglycaemia and DKA
- No significant differences
Original publication
Faster‐acting insulin aspart versus insulin aspart for adults with type 1 diabetes treated with non‐automated insulin pump and continuous glucose monitoring—A double‐blind randomized controlled crossover trial. Diabetes Obes Metab. Published 24 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →